Baxter's PrisMax Adopted By Hamilton Health Care System
Zacks Investment Research | Aug 14, 2019 09:13PM ET
Baxter International Inc. (NYSE:BAX) recently announced that Hamilton Health Care System will now be the first health system in the United States to utilize the former’s new PrisMax system. This new and advanced technology is expected to enhance patient care.
For investor’s notice, Baxter’s innovative PrisMax system for managing acute kidney injury (AKI) has received the FDA approval and is available in the Unites States. This in turn will boost Baxter’s Acute Therapies profile.
PrixMax System at a Glance
The innovative PrisMax system has been created with the help of real-world input from more than 650 healthcare providers globally. The system provides advanced technology that can be used for the treatment of critically injured patients.
Notably, PrisMax is available in the intensive care units in more than 20 countries across Europe and Asia-Pacific. Per management, the company plans to bring additional markets on board through 2020.
Adoption of PrisMax System
With the adoption of the new innovative system, Hamilton Health Care expects to improve its critical care services that include the capability to offer treatment to those patients developing AKI. PrisMax system consists of new digital health features that will enable hospitals to connect the system to electronic medical record (EMR) platforms.
As a result, the nurses will have to spend less time the ICU to manually document treatment data, which in turn lower the risk of transcription errors.
Baxter’s Acute Therapies Profile Update
Baxter’s performance in acute therapies is being driven by improving utilization for CRRT globally, and increased demand for multi-organ support products. In fact, the second quarter 2019 performance primarily came on the back of ongoing rollout of the PrisMax next-generation technology for CRRT and Therapeutic Plasma Exchange.
For the Acute Therapies business, Baxter, which is a worldwide leading player in acute care, expects growth of approximately 7% to 8% on a year-over-year basis in 2019.
Market Prospects
Per a report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.